Señales en vivo de AMYT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 abr 2024 @ 16:00):

Stats
Volumen de hoy	2.38M
Volumen promedio	0.00
Capitalización de mercado	942.77M
EPS	$0 ( 2023-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	39.73
ATR14	$0.0580 (0.39%)

Volumen Correlación

Largo: 0.18 (neutral)

Corto: 0.00 (neutral)

Signal:(69.184) Neutral

Amryt Pharma plc Correlación

10 Correlaciones Más Positivas
SUMO	0.97
DSPG	0.964
IDCC	0.946
NTUS	0.945
FSTR	0.945
STAY	0.941
HCCI	0.938
SENEA	0.935
SOHOB	0.935
ACLS	0.934

10 Correlaciones Más Negativas
DSGN	-0.991
CSSE	-0.989
YTEN	-0.98
FWRD	-0.978
CASA	-0.974
THTX	-0.974
ESPR	-0.97
PFSW	-0.97
GRTX	-0.968
BBLG	-0.963

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amryt Pharma plc Correlación - Moneda/Commodity

-0.43
( neutral )

-0.49
( neutral )

-0.67
( moderate negative )

-0.60
( weak negative )

0.51
( weak )

Amryt Pharma plc Finanzas

Annual	2021
Ingresos:	$222.54M
Beneficio Bruto:	$116.42M (52.32 %)
EPS:	$-0.573

FY	2021
Ingresos:	$222.54M
Beneficio Bruto:	$116.42M (52.32 %)
EPS:	$-0.573

FY	2020
Ingresos:	$182.61M
Beneficio Bruto:	$63.58M (34.82 %)
EPS:	$-3.30

FY	2019
Ingresos:	$58.12M
Beneficio Bruto:	$16.12M (27.74 %)
EPS:	$-4.30

Financial Reports:

No articles found.

Amryt Pharma plc

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.